Increased impact of a contraceptive vaginal ring with ethinyl estradiol and nestorone on C-reactive protein
article
Objective & study design
In a parallel design, 23 and 22 healthy pre-menopausal women were randomly administered a contraceptive vaginal ring (CVR) delivering 150/15 μg Nestorone®/ethinyl estradiol (EE) daily or an oral contraceptive (OC) containing levonorgestrel and EE (150/30 μg) for three cycles, to compare the effects on C-reactive protein and other markers of inflammation. ANCOVA was performed with baseline values as covariate.
Results
The CVR caused [estimate of difference (95% CI), 109% (16–275%)] higher levels of CRP than the OC, while no difference was observed for leukocyte 1% (−13/+17%) and monocyte counts 6% (−9/+23%). The greater increase in CRP was confined to CVR recipients exhibiting low pre-treatment CRP-levels, whereas no difference was observed in the increases for recipients in the highest tertile of pre-treatment CRP levels.
Conclusion
The difference in CRP rise in CVR and OC users does not correspond with the effects on other markers of inflammation and is most likely due to a specific difference in the effect of ethinyl-estradiol combined with nestorone in cases with low CRP. Chemicals / CAS C reactive protein, 9007-41-4; elcometrine, 7759-35-5; ethinylestradiol, 57-63-6; ethinylestradiol plus norgestrel, 8056-51-7; C-Reactive Protein, 9007-41-4; Ethinyl Estradiol, 57-63-6; Norprogesterones; ST 1435, 7759-35-5
In a parallel design, 23 and 22 healthy pre-menopausal women were randomly administered a contraceptive vaginal ring (CVR) delivering 150/15 μg Nestorone®/ethinyl estradiol (EE) daily or an oral contraceptive (OC) containing levonorgestrel and EE (150/30 μg) for three cycles, to compare the effects on C-reactive protein and other markers of inflammation. ANCOVA was performed with baseline values as covariate.
Results
The CVR caused [estimate of difference (95% CI), 109% (16–275%)] higher levels of CRP than the OC, while no difference was observed for leukocyte 1% (−13/+17%) and monocyte counts 6% (−9/+23%). The greater increase in CRP was confined to CVR recipients exhibiting low pre-treatment CRP-levels, whereas no difference was observed in the increases for recipients in the highest tertile of pre-treatment CRP levels.
Conclusion
The difference in CRP rise in CVR and OC users does not correspond with the effects on other markers of inflammation and is most likely due to a specific difference in the effect of ethinyl-estradiol combined with nestorone in cases with low CRP. Chemicals / CAS C reactive protein, 9007-41-4; elcometrine, 7759-35-5; ethinylestradiol, 57-63-6; ethinylestradiol plus norgestrel, 8056-51-7; C-Reactive Protein, 9007-41-4; Ethinyl Estradiol, 57-63-6; Norprogesterones; ST 1435, 7759-35-5
Topics
C-reactive proteinContraceptive vaginal ringInflammationNestoroneOral contraceptivesC reactive proteinelcometrineethinylestradiolethinylestradiol plus norgestreladultarticleclinical articlecontrolled studyfemalehumaninflammationleukocyte countmenstrual cyclemonocyteoral contraceptionpremenopauseprotein blood levelrandomized controlled trialvagina ringAdolescentAdultC-Reactive ProteinContraceptive Devices, FemaleEthinyl EstradiolFemaleHumansNorprogesteronesYoung Adult
TNO Identifier
954336
ISSN
0039128X
Source
Steroids, 77(13), pp. 1483-1486.
Pages
1483-1486
Files
To receive the publication files, please send an e-mail request to TNO Repository.